Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF BUSINESS OFFICER

SVP & CHIEF COMMERCIAL OFFICER

SVP & CHIEF MEDICAL OFFICER

PRESIDENT & CEO

SVP & CHIEF OPERATING OFFICER

EVP, CFO, SECRY & TREAS.

SVP & CHIEF SCIENTIFIC OFFICER

SVP & CHIEF TECHNICAL OFFICER

Chief Business Officer

See remarks

EVP, CFO, Secry & Treas.

SVP & CMO

EVP, CFO, Secretary & Treas.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibod...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-12	Premium	acquired	Premium	Premium	Premium	-
2024-03-05	Premium	sold	Premium	Premium	Premium	CHIEF BUSINESS OFFICER
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP & CHIEF COMMERCIAL OFFICER
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP & CHIEF MEDICAL OFFICER
2024-02-12	Premium	acquired	Premium	Premium	Premium	PRESIDENT & CEO
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF OPERATING OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	EVP, CFO, SECRY & TREAS.
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF SCIENTIFIC OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF COMMERCIAL OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	CHIEF BUSINESS OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF MEDICAL OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF TECHNICAL OFFICER
2023-12-21	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2023-12-15	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2023-12-13	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2023-12-11	Premium	bought	Premium	Premium	Premium	-
2023-12-11	Premium	bought	Premium	Premium	Premium	-
2023-12-11	Premium	bought	Premium	Premium	Premium	-
2023-12-11	Premium	bought	Premium	Premium	Premium	-
2023-12-08	Premium	bought	Premium	Premium	Premium	-
2023-12-08	Premium	bought	Premium	Premium	Premium	-
2023-12-07	Premium	bought	Premium	Premium	Premium	-
2023-12-07	Premium	bought	Premium	Premium	Premium	-
2023-11-29	Premium	bought	Premium	Premium	Premium	-

YMAB - Y-mAbs Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for YMAB